Institute of Biochemistry I, University Hospital, Jena, Germany.
Proteomics Clin Appl. 2010 Dec;4(12):953-61. doi: 10.1002/prca.201000051. Epub 2010 Nov 22.
Aim of the study was to identify long-term differences of middle and high-molecular-weight serum constituents under high- and low-flux hemodialysis treatments. Thus, the entire predialytic serum proteomes had to be analyzed using identical hemodialysis membrane material but with different cut-off values.
A cross-over study and a global native chromatographic proteomic approach were used to analyze serum compositions of 16 patients suffering from end-stage renal disease.
No significant or reproducible differences were found between predialytic serum samples from high- and low-flux dialysis treatments using UV-absorbance and fluorescence spectrometry, PMF, or sequence tags. In contrast, there are characteristic differences in the predialytic serum composition of the patients considered and two control sets, which include samples obtained post-dialytically from patients and samples from healthy controls. Only a fraction of β(2)-microglobulin, an example of so-called middle molecules, exhibits the expected molecular weight. A small fraction was found with high molecular weight unaffected by any dialysis treatment. Moreover, immunoreactivity of fragments of β(2)-microglobulin, surprisingly, was also not affected by the cut-off of dialysis membranes.
Thus, simply increasing the pore size of a hemodialysis membrane may not have any long-term effect on serum composition.
本研究旨在比较高通量和低通量血液透析治疗下中高分子量血清成分的长期差异。因此，必须使用相同的血液透析膜材料但采用不同的截止值来分析整个透析前血清蛋白质组。
采用交叉研究和全天然色谱蛋白质组学方法分析了 16 例终末期肾病患者的血清成分。
采用紫外吸收和荧光光谱法、PMF 或序列标签对高通量和低通量透析治疗的透析前血清样本进行分析，未发现有显著或可重复的差异。相比之下，考虑到患者和两个对照组（包括患者透析后的样本和健康对照者的样本）的透析前血清成分存在特征性差异。只有β(2)-微球蛋白（所谓的中分子的一个例子）的一小部分具有预期的分子量。一小部分不受任何透析治疗影响的高分子量物质被发现。此外，β(2)-微球蛋白片段的免疫反应性也出人意料地不受透析膜截止值的影响。
因此，仅仅增加血液透析膜的孔径可能对血清成分没有任何长期影响。
